JD Supra4h
FDA’s Semaglutide Shortage Resolution: Legal Implications and Risks for Compounding Pharmacies
Last month, the U.S. Food and Drug Administration (the “FDA”) announced in a Declaratory Order the resolution of the shortage of semaglutide ...
BC Technology6h
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Weight Loss Drug Zepbound(R)
Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide ("FTS") rodent biodistribution study.
NBC Los Angeles9h
Zepbound copycats remain online despite FDA ban
Copycat versions of Eli Lilly’s diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They’re ...
Insurance Coverage For Ozempic, Zepbound Went Down In 2025
While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...
Knowridge Science Report16h
Weekly injections reduce weight and knee pain in people with obesity
A new study has found that a once-weekly injection of semaglutide, a medication originally developed for diabetes and weight ...
Weight loss drug Mounjaro launched in India: Know price, how it works, side-effects, and if it’s more effective than Ozempic
The global weight-loss drug market is expected to reach $150 billion in the next decade. By 2026, semaglutide (the active ...
Weight-loss drug Mounjaro in India: Is it better than Ozempic?
US pharmaceutical company Eli Lilly has launched Mounjaro, a diabetes and weight-loss drug, in India. Priced at Rs 3,500 for a 2.5 mg vial, the ‘game-changing’ medication has debuted in the Indian ...
Mounjaro hits shelves in India: How Eli Lilly’s weight loss drug compares with Ozempic — price, side effects and more
Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...